CD8A and melanoma: - Pembro combo showed ORR 10.2% (did not meet ORR endpoint in PD-1 refractory melanoma); also showed ORR 41% in advanced melanoma with low PD-1high CTLA-4high CD8+ CTL (n=22)- Neoadjuvant combo with Nivolumab: Pre-operative response rate 77.8% (n=9)- No tumor retention of the drug- Showed systemic immune responses- Well tolerated